Fig. 1
CLDN6-ADC as a novel therapeutic option to target GCTs. A Raw flow cytometry data of CLDN6-FITC stained (blue) GCT cell lines, including their cisplatin-resistant sublines, and non-cancerous control cells compared with unstained controls (grey). B Relative CLDN6 expression in GCT cell lines and non-cancerous control cells. ACTB and GAPDH were used as housekeeping genes. C LD50 values (ng / ml) acquired by XTT cell viability assays 72 h after treatment with CLDN6-ADC and color-coded changes in cell cycle distribution (G2 / M = green, mitotic catastrophe = red, changes < 5 % = grey) upon treatment with CLDN6-ADC as compared to treatment with the CLDN6 antibody alone in GCT cell lines, including their cisplatin-resistant sublines, as well as fibroblast control cells (MPAF). D Lollipop graph summarizing relative number of apoptotic cells in GCT cell lines and fibroblast control cells after treatment with either CLDN6-ADC or CLDN6 antibody alone